Cargando…

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

Aim To evaluate the effect of alirocumab on frequency of standard apheresis treatments [weekly or every 2 weeks (Q2W)] in heterozygous familial hypercholesterolaemia (HeFH). Methods and results ODYSSEY ESCAPE (NCT02326220) was a double-blind study in 62 HeFH patients undergoing regular weekly or Q2W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moriarty, Patrick M., Parhofer, Klaus G., Babirak, Stephan P., Cornier, Marc-Andre, Duell, P. Barton, Hohenstein, Bernd, Leebmann, Josef, Ramlow, Wolfgang, Schettler, Volker, Simha, Vinaya, Steinhagen-Thiessen, Elisabeth, Thompson, Paul D., Vogt, Anja, von Stritzky, Berndt, Du, Yunling, Manvelian, Garen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Fasttrack Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233802/ https://www.ncbi.nlm.nih.gov/pubmed/27572070 http://dx.doi.org/10.1093/eurheartj/ehw388

Ejemplares similares

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
por: Cannon, Christopher P., et al.
Publicado: (2015)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015)

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE
por: Banach, Maciej, et al.
Publicado: (2021)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2009)

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
por: Steg, Ph. Gabriel, et al.
Publicado: (2011)

The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy
por: Gold, Michael R., et al.
Publicado: (2011)

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy
por: Tardif, Jean-Claude, et al.
Publicado: (2011)

One year follow-up of the multi-centre European PARTNER transcatheter heart valve study
por: Lefèvre, Thierry, et al.
Publicado: (2011)

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation
por: Matsa, Elena, et al.
Publicado: (2011)

Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study
por: Tanaka, Hidekazu, et al.
Publicado: (2010)

Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation
por: Hjortnaes, Jesper, et al.
Publicado: (2010)

Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity® catheter system and the EnligHTN™ multi-electrode renal denervation catheter
por: Templin, Christian, et al.
Publicado: (2013)

Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial
por: Worthley, Stephen G., et al.
Publicado: (2013)

PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice
por: Parhofer, Klaus G., et al.
Publicado: (2019)

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial
por: Goodman, Shaun G., et al.
Publicado: (2023)

Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score–Matched Analysis of the ODYSSEY OUTCOMES Trial
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
por: Müller-Wieland, Dirk, et al.
Publicado: (2019)

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
por: White, Harvey D, et al.
Publicado: (2019)

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
por: Schwartz, Gregory G, et al.
Publicado: (2023)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
por: Langslet, Gisle, et al.
Publicado: (2020)

Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP–GPRD)
por: Boggon, Rachael, et al.
Publicado: (2011)

Variants in the 3′ untranslated region of the KCNQ1-encoded K(v)7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner
por: Amin, Ahmad S., et al.
Publicado: (2012)

A novel clinical method for quantification of regional left ventricular pressure–strain loop area: a non-invasive index of myocardial work
por: Russell, Kristoffer, et al.
Publicado: (2012)

Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
por: Lauten, Alexander, et al.
Publicado: (2011)

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial
por: Pitt, Bertram, et al.
Publicado: (2011)

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
por: Goto, Shinya, et al.
Publicado: (2010)

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan, et al.
Publicado: (2010)

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
por: Haynes, Richard, et al.
Publicado: (2013)

The German Aortic Valve Registry (GARY): in-hospital outcome
por: Hamm, Christian W., et al.
Publicado: (2014)

Impact of cardiac magnetic resonance imaging on human lymphocyte DNA integrity
por: Fiechter, Michael, et al.
Publicado: (2013)

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study(†)
por: Budera, Petr, et al.
Publicado: (2012)

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
por: Borer, Jeffrey S., et al.
Publicado: (2012)

Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
por: Steg, Ph Gabriel, et al.
Publicado: (2012)

Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium(†)
por: Riegger, Julia, et al.
Publicado: (2016)

A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve
por: Bairey Merz, C. Noel, et al.
Publicado: (2016)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8jr9g4hejk7litrblnf24v6qge